JP2023524853A5 - - Google Patents

Info

Publication number
JP2023524853A5
JP2023524853A5 JP2022568380A JP2022568380A JP2023524853A5 JP 2023524853 A5 JP2023524853 A5 JP 2023524853A5 JP 2022568380 A JP2022568380 A JP 2022568380A JP 2022568380 A JP2022568380 A JP 2022568380A JP 2023524853 A5 JP2023524853 A5 JP 2023524853A5
Authority
JP
Japan
Prior art keywords
nucleic acid
ipsc
sequence
pluripotent stem
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524853A (ja
Filing date
Publication date
Priority claimed from GBGB2006903.5A external-priority patent/GB202006903D0/en
Application filed filed Critical
Publication of JP2023524853A publication Critical patent/JP2023524853A/ja
Publication of JP2023524853A5 publication Critical patent/JP2023524853A5/ja
Pending legal-status Critical Current

Links

JP2022568380A 2020-05-11 2021-05-11 改変されたiPSC Pending JP2023524853A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2006903.5A GB202006903D0 (en) 2020-05-11 2020-05-11 Modified iPSCs
GB2006903.5 2020-05-11
PCT/GB2021/051125 WO2021229212A1 (en) 2020-05-11 2021-05-11 Modified ipscs

Publications (2)

Publication Number Publication Date
JP2023524853A JP2023524853A (ja) 2023-06-13
JP2023524853A5 true JP2023524853A5 (cg-RX-API-DMAC7.html) 2024-04-19

Family

ID=71135035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568380A Pending JP2023524853A (ja) 2020-05-11 2021-05-11 改変されたiPSC

Country Status (11)

Country Link
US (1) US20240016853A1 (cg-RX-API-DMAC7.html)
EP (1) EP4149492A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023524853A (cg-RX-API-DMAC7.html)
CN (1) CN115515606A (cg-RX-API-DMAC7.html)
AU (1) AU2021271220A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022654A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178047A1 (cg-RX-API-DMAC7.html)
GB (1) GB202006903D0 (cg-RX-API-DMAC7.html)
IL (1) IL298074A (cg-RX-API-DMAC7.html)
MX (1) MX2022014116A (cg-RX-API-DMAC7.html)
WO (1) WO2021229212A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2022714B1 (en) 2019-03-11 2020-09-18 Academisch Ziekenhuis Leiden Optimised RAG1 deficient SCID Gene Therapy
GB201911957D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of producing haemogenic progenitor cells from pluripotent stem cells
GB202111214D0 (en) * 2021-08-03 2021-09-15 Adaptimmune Ltd Modified ipscs
GB202205572D0 (en) 2022-04-14 2022-06-01 Adaptimmune Ltd Engineered T cells
KR20260024373A (ko) * 2023-05-05 2026-02-20 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 다중-수용체 자연 살해 세포
CN118421559B (zh) * 2024-07-04 2024-09-27 成都赛济元生物医药有限公司 定向分化淋巴造血前体细胞的小分子组合、试剂盒及方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
US12194083B2 (en) * 2014-07-18 2025-01-14 Hiroshi Kawamoto Method for establishing pluripotent stem cells bearing genes encoding antigen specific T cell receptor
AU2015290554A1 (en) * 2014-07-18 2017-03-09 Kyoto University Method for inducing T cells for cell-based immunotherapy from pluripotent stem cells
KR102929174B1 (ko) * 2015-10-30 2026-02-20 더 리전츠 오브 더 유니버시티 오브 캘리포니아 줄기세포로부터 t-세포를 생산하는 방법 및 상기 t-세포를 이용한 면역치료 방법
MX395611B (es) * 2016-04-08 2025-03-25 Adaptimmune Ltd Receptores de celulas t.
KR102614675B1 (ko) * 2016-04-15 2023-12-19 메모리얼 슬로안 케터링 캔서 센터 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
EP3528819A1 (en) * 2016-12-21 2019-08-28 Cellectis Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy
US10934336B2 (en) * 2017-04-13 2021-03-02 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
US12350312B2 (en) * 2017-09-06 2025-07-08 Fred Hutchinson Cancer Center Methods for improving adoptive cell therapy
WO2020022512A1 (ja) * 2018-07-26 2020-01-30 国立大学法人京都大学 外来抗原レセプター遺伝子導入細胞の製造方法
GB201911953D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd T cell production fram RAG inacivated iPSCs

Similar Documents

Publication Publication Date Title
JP7451858B2 (ja) クローディン6特異的免疫受容体およびt細胞エピトープ
US12404492B2 (en) Methods for enhancing efficacy of therapeutic immune cells
US20240024476A1 (en) CAR Cells and Polyspecific Binding Molecules for Treating Solid Tumor
US10561686B2 (en) Modified cell expansion and uses thereof
KR102733541B1 (ko) 유전자 치료법
Ho et al. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction
KR102703764B1 (ko) 클라우딘-18.2-특이적 면역수용체 및 t 세포 에피토프
EP3586852A1 (en) Modified cell expansion and uses thereof
JP6929867B2 (ja) がんに対する免疫療法で使用するための形質移入t細胞およびt細胞受容体
CN110072885A (zh) TGFβ信号转换器
JP2017512054A (ja) 三官能性t細胞−抗原カプラ及び方法並びにこれらの使用
AU2018396083A1 (en) Method for improving production of CAR T cells
US20210379149A1 (en) Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
Garber et al. Adoptive T-cell therapy for Leukemia
WO2023150510A2 (en) Car and polyspecific binding molecules targeting solid tumors
CN117987435A (zh) 氧依赖性嵌合抗原受体表达及其应用
JP2022506781A (ja) メソテリンを標的とする免疫療法
US20230133564A1 (en) Cd3-fusion protein and uses thereof
KR20220095228A (ko) 암의 t 세포 치료를 위한 세포독성 효과기 기억 t 세포를 생산하는 방법
Dotti Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies
US20240299452A1 (en) Rapamycin and Cell Therapy
CA3137808A1 (en) Cd5 specific t cell receptor cell or gene therapy
CN119143886A (zh) 靶向实体瘤的car和多特异性结合分子
HK40086170A (en) Methods for enhancing efficacy of therapeutic immune cells
HK1248273A1 (en) Methods for enhancing efficacy of therapeutic immune cells